204863-53-6

Usage

Uses

Used in Pharmaceutical Research:
4-(4-OXO-PIPERIDINE-1-CARBONYL)-BENZAMIDE is utilized as a synthetic building block for the creation of biologically active molecules. Its incorporation into various chemical structures allows for the development of compounds with potential therapeutic applications.
Used in Drug Development:
In the pharmaceutical industry, 4-(4-OXO-PIPERIDINE-1-CARBONYL)-BENZAMIDE is employed as a precursor in the synthesis of new drug candidates. Its versatile chemical properties make it suitable for the design of molecules targeting specific diseases.
Used in the Study of Biological Systems:
4-(4-OXO-PIPERIDINE-1-CARBONYL)-BENZAMIDE also serves as a valuable tool in biological research, where it can be used to probe and understand complex biological mechanisms. Its interaction with biological targets can provide insights into disease pathways and potential therapeutic interventions.
While the specific applications and industries for 4-(4-OXO-PIPERIDINE-1-CARBONYL)-BENZAMIDE are not explicitly detailed in the provided materials, the general uses outlined above are inferred from its role in pharmaceutical research and development, as well as its potential in the broader study of biological systems.

Upstream product

• 16588-16-2 ethyl 4-chloro-3-nitrobenzoate 
• 367-80-6 ethyl 4-fluoro-3-nitrobenzoate 
• 453-71-4 3-nitro-4-fluorobenzoic acid 
• 204863-52-5 ethyl 4-ethoxycarbonylmethylsulfanyl-3-nitrobenzoate 
• 96-99-1 4-chloro-3-nitrobenzoate 
• 204863-51-4 4-ethoxycarbonylmethylsulfanyl-3-nitrobenzoic acid 

Downstream Products

• 272437-84-0 3-oxo-3,4-dihydro-2H-benzo[b][1,4]thiazine-6-carboxylic acid 
• 1392139-27-3 (Z)-2-(2-methylbenzylidene)-3-oxo-3,4-dihydro-2H-benzo[b][1,4]thiazine-6-carboxylic acid 
• 1392139-28-4 (Z)-2-(2-methoxybenzylidene)-3-oxo-3,4-dihydro-2H-benzo[b][1,4]thiazine-6-carboxylic acid 
• 1392139-45-5 C₂₄H₂₇N₃O₂S 
• 1392139-46-6 C₂₄H₂₇N₃O₃S 

Relevant academic research and scientific papers

Discovery of a Plasmodium falciparum Glucose-6-phosphate Dehydrogenase 6-phosphogluconolactonase Inhibitor (R,Z)-N-((1-Ethylpyrrolidin-2-yl)methyl)-2- (2-fluorobenzylidene)-3-oxo-3,4-dihydro-2H-benzo[b][1,4]thiazine-6-carboxamide (ML276) that reduces parasite growth in vitro

A high-throughput screen of the NIH's MLSMR collection of ～340000 compounds was undertaken to identify compounds that inhibit Plasmodium falciparum glucose-6-phosphate dehydrogenase (Pf G6PD). PfG6PD is important for proliferating and propagating P. falciparum and differs structurally and mechanistically from the human orthologue. The reaction catalyzed by glucose-6-phosphate dehydrogenase (G6PD) is the first, rate-limiting step in the pentose phosphate pathway (PPP), a key metabolic pathway sustaining anabolic needs in reductive equivalents and synthetic materials in fast-growing cells. In P. falciparum, the bifunctional enzyme glucose-6-phosphate dehydrogenase-6- phosphogluconolactonase (Pf GluPho) catalyzes the first two steps of the PPP. Because P. falciparum and infected host red blood cells rely on accelerated glucose flux, they depend on the G6PD activity of PfGluPho. The lead compound identified from this effort, (R,Z)-N-((1-ethylpyrrolidin-2-yl)methyl)-2-(2- fluorobenzylidene)-3-oxo-3,4-dihydro-2H-benzo[b][1,4]thiazine-6-carbox-amide, 11 (ML276), is a submicromolar inhibitor of PfG6PD (IC50 = 889 nM). It is completely selective for the enzyme's human isoform, displays micromolar potency (IC50 = 2.6 μM) against P. falciparum in culture, and has good drug-like properties, including high solubility and moderate microsomal stability. Studies testing the potential advantage of inhibiting Pf G6PD in vivo are in progress.

HYDROXAMIC ACID DERIVATIVE AND MMP INHIBITOR CONTAINING THE SAME AS ACTIVE INGREDIENT

A hydroxamic acid derivative represented by the following general formula (1) having selective MMP inhibitory activity, , wherein R1 andR2 each represents hydrogen atom, lower alkyl group, lower haloalkyl etc., X represents methylene

Hydroxamic acid derivatives

A hydroxamic acid derivative represented by formula (1) or a prodrug thereof, or a pharmaceutically acceptable salt thereof, which has a matrix metalo-proteinase inhibitor.

AMINE COMPOUNDS

The present invention provide a compound of the formula:wherein ring A represents an aromatic ring optionally having substituents; B, Y and Ya are the same or different and each represents a bond, etc.; R1 and R2 are the same or different and each represents a hydrogen atom, etc.; R3 represents a hydrogen atom, etc.; R4 and R5 are the same or different and each represents a hydrogen, etc.; R6 represents an indolyl group optionally having substituents; and Z and Za are the same or different and each represents a hydrogen atom, etc.; or a salt thereof or a prodrug thereof, having a somatostatin receptor binding inhibition activity and is useful for preventing and/or treating diseases associated with somatostatin.

Quantitative structure-activity relationship study of N-(3-oxo-3,4- dihydro-2H-benzol[1,4]thiazine-6-carbonyl)guanidines as potent na/h exchange inhibitors

We have previously reported that N-(4-isopropyl-2,2-dimethyl-3-oxo-3,4- dihydro-2H-benzo[1,4]oxazine-6carbonyl)guanidine (4b) methanesulfonate salt (KB-R9032) is a potent and highly water-soluble Na/H exchange inhibitor. In a series of studies on Na/H exc